Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
DA

NASDAQ · DAWN

Day One Biopharmaceuticals, Inc.

Healthcare · Biotechnology

$21.53

Up+$0.00 (+0.00%)

Updated Aug 22, 2026, 6:59 PM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
865.35M
P/E ratio
-5.74
Dividend yield
0.00%
52-week range
$5.64 – $21.53
Volume
2.99M
Avg. volume
2.2M

Price performance

DAWN price history

1M range · 0 trading sessions · Daily adjusted prices

DAWN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest DAWN news

The latest Smart Investors Daily articles mentioning DAWN.

Stock researchCompany · Overview

DAWN research

Overview

Company profile and research snapshot.

Company profile

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$26.00
Implied upside
—
Analysts
—
DAWN recent ratings
DateFirmRatingTarget
Mar 11, 2026JP MorganNeutral—
Mar 10, 2026HC Wainwright & Co.Neutral—
Mar 9, 2026WedbushNeutral—
Mar 6, 2026Jones TradingHold—
Mar 6, 2026NeedhamHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Mar 12, 2026

A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum

Day One Biopharmaceuticals (DAWN) has drawn investor attention after strong recent share performance, with returns of 65% over the past week and 81% over the past month, prompting closer review of its fundamentals. See our latest analysis for Day One Biopharmaceuticals. With the share price now at $21.25, Day One Biopharmaceuticals has seen strong momentum recently, including a 90 day share price return of 152.38% and a 1 year total shareholder return of 141.75%. This suggests investors are...

Yahoo · Mar 11, 2026

Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More

Pre-Market Stock Futures: Futures are trading flat as we hit the mid-point of the trading week, and while we didn’t see the snapback rally that was the star of the show Monday, at least all four major indices held their own as the conflict in Iran grinds on. The Nasdaq was able to eke out ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By